GH Research PLC
corporate_fare Company Profile
GH Research PLC (NASDAQ:GHRS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for GHRS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for GHRS spans 6-K, F-3, 424B5.
Recent high-impact activity:
- GH Research Q3: FDA-Aligned Pivotal TRD Design, EoP2 Set for Q1 2027, $350.6M Cash
- GH Research Q2 2026: $362.7M Cash Runway, FDA Phase 3 Alignment, and Key Patent Wins
- GH Research Reports 100% Remission in Phase 2a Postpartum Depression Trial for GH001
- GH001 Shows Strong Efficacy in Anhedonia, Anxiety, and Quality of Life, Independent of Prior Treatment Failures
- GH Research Files $400M Universal Shelf Registration for Future Capital Raises
Financial Snapshot
Short Interest & Short Volume
6.51 days to coverFINRA reported short interest of 2,079,373 shares in GHRS as of the October 30, 2026 settlement, a 3.4% increase from the prior period — about 6.5 days to cover at its recent average daily volume. On November 19, 2026, 53.0% of GHRS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
GHRS files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.